Cargando…
Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
Autores principales: | Grassi, Paolo, Verzoni, Elena, Mennitto, Alessia, Procopio, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182224/ https://www.ncbi.nlm.nih.gov/pubmed/28078236 http://dx.doi.org/10.21037/tau.2016.11.06 |
Ejemplares similares
-
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016) -
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017) -
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018) -
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
por: Donskov, Frede, et al.
Publicado: (2019) -
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
por: Schmidinger, Manuela, et al.
Publicado: (2022)